Laia G. C.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase 3 Randomized Double-Blind Study of Niraparib Tosilate Monohydrate Versus Placebo in HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Elacestrant and Everolimus in ER+/HER2-, ESR1-Mutated Advanced Breast Cancer Post-Endocrine and CDK4/6 Inhibitors
- PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER (THE CADILLAC STUDY)
Data & Insights
Has run more than one trial at 17 of 101 partner sites.
Specializations
Early Stage Breast Cancer
This investigator specializes in researching hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, with particular focus on monitoring minimal residual disease through ctDNA analysis.
- HR+/HER2- breast cancer therapies
- Early-stage disease management
- Molecular disease monitoring
Additional expertise includes evaluating treatment efficacy in premenopausal women with ER+/HER2- breast cancer with specific Ki67 expression patterns.
Advanced Breast Cancer
The investigator conducts research on advanced breast cancer treatments, particularly focusing on patients with ESR1-mutated tumors who have progressed after previous therapies.
- Endocrine therapy resistance
- CDK4/6 inhibitor treatments
- Novel therapeutic combinations
Research interests extend to innovative treatment approaches for hormone receptor-positive advanced disease.
Molecular and Genetic Studies
Research focus includes BRCA-mutated breast cancers and triple-negative breast cancer (TNBC), with emphasis on molecular disease monitoring through circulating tumor DNA.
- ctDNA analysis and monitoring
- BRCA mutation studies
- Targeted therapy development
The investigator explores novel approaches in molecular-based treatment strategies and disease monitoring.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.